|Bid||2.6000 x 900|
|Ask||2.7300 x 800|
|Day's Range||2.6100 - 2.8000|
|52 Week Range||1.5500 - 5.4100|
|Beta (5Y Monthly)||0.56|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
Subscribe to Yahoo Finance Plus to view Fair Value for ATHE
Data from a preclinical study shows that treatment with Alterity's (ATHE) lead candidate improved motor performance and general function in monkeys with experimentally-induced Parkinson's disease.
MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be hosting an investor webcast on Wednesday, 6 December 2023 in Australia / Tuesday, 5 December 2023 in the United States. Details are listed below and registration is required. The call will be hosted by Alterity’s CEO Dr. David Stam
Shares in Alterity Therapeutics soared after the biotech firm disclosed promising new clinical trial data for its Parkinson's disease treatment.